Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma.
FASN
de novo lipogenesis
hepatocellular carcinoma
precision medicine
tumor metabolism
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
09
2019
accepted:
28
11
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
11
1
2020
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is one of the most common solid tumors worldwide, characterized by clinical aggressiveness, resistance to conventional chemotherapy, and high lethality. Consequently, there is an urgent need to better delineate the molecular pathogenesis of HCC to develop new preventive and therapeutic strategies against this deadly disease. Noticeably, emerging evidence indicates that proteins involved in lipid biosynthesis are important mediators along the development and progression of HCC in humans and rodents. Here, we provide a comprehensive overview of: (a) The pathogenetic relevance of lipogenic proteins involved in liver carcinogenesis, with a special emphasis on the master fatty acid regulator, fatty acid synthase (FASN); (b) The molecular mechanisms responsible for unrestrained activation of FASN and related fatty acid biosynthesis in HCC; (c) The findings in experimental mouse models of liver cancer and their possible clinical implications; (d) The existing potential therapies targeting FASN. A consistent body of data indicates that elevated levels of lipogenic proteins, including FASN, characterize human hepatocarcinogenesis and are predictive of poor prognosis of HCC patients. Pharmacological or genetic blockade of FASN is highly detrimental for the growth of HCC cells in both
Identifiants
pubmed: 31921669
doi: 10.3389/fonc.2019.01412
pmc: PMC6927283
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1412Subventions
Organisme : NCI NIH HHS
ID : R01 CA136606
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2019 Che, Paliogiannis, Cigliano, Pilo, Chen and Calvisi.
Références
Cancer Cell. 2004 Mar;5(3):253-61
pubmed: 15050917
Chin J Cancer Res. 2016 Jun;28(3):377-9
pubmed: 27478324
Gastroenterology. 2011 Mar;140(3):1071-83
pubmed: 21147110
Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):631-640
pubmed: 30578319
Curr Drug Targets. 2015;16(2):156-63
pubmed: 25537655
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Future Oncol. 2010 Apr;6(4):551-62
pubmed: 20373869
Cancer Biol Ther. 2006 Aug;5(8):978-85
pubmed: 16855382
Cell. 2012 Apr 13;149(2):274-93
pubmed: 22500797
Cell Chem Biol. 2016 Jun 23;23(6):678-88
pubmed: 27265747
Liver Int. 2017 Jan;37(1):80-89
pubmed: 27264722
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Cancer. 2016 Nov;16(11):732-749
pubmed: 27658529
BMC Cancer. 2012 Jul 06;12:280
pubmed: 22769244
Gastroenterology. 2019 Jan;156(2):492-509
pubmed: 30404026
Sci Rep. 2016 Feb 09;6:20484
pubmed: 26857837
N Engl J Med. 1993 Jun 24;328(25):1797-801
pubmed: 7684822
Expert Opin Drug Discov. 2016 Dec;11(12):1187-1199
pubmed: 27701891
Org Lett. 2014 Mar 7;16(5):1414-7
pubmed: 24552542
Cell Metab. 2013 Aug 6;18(2):153-61
pubmed: 23791484
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8695-9
pubmed: 7567999
Eur J Cancer. 2005 Jun;41(9):1316-22
pubmed: 15869874
Hepatology. 2008 Oct;48(4):1312-27
pubmed: 18821591
J Biol Chem. 2016 Nov 18;291(47):24628-24640
pubmed: 27681596
Hepatology. 2007 Feb;45(2):269-76
pubmed: 17256759
Cell Prolif. 2008 Feb;41(1):59-85
pubmed: 18211286
Cancer Discov. 2018 Aug;8(8):1006-1025
pubmed: 29903879
Cancer Res. 2004 Mar 15;64(6):2070-5
pubmed: 15026345
Int J Biochem Mol Biol. 2010 Jul 18;1(1):69-89
pubmed: 20706604
FEBS J. 2016 Aug;283(15):2767-78
pubmed: 26881388
J Hepatol. 2015 Dec;63(6):1378-89
pubmed: 26282231
Biochem J. 1988 Dec 1;256(2):357-61
pubmed: 3223916
Nat Struct Mol Biol. 2007 Aug;14(8):704-9
pubmed: 17618296
Oncol Rep. 2016 Sep;36(3):1709-16
pubmed: 27461404
World J Hepatol. 2016 Mar 28;8(9):421-38
pubmed: 27028578
Curr Drug Targets. 2016;17(15):1735-1746
pubmed: 27138758
Cancer Cell. 2017 Dec 11;32(6):807-823.e12
pubmed: 29232555
J Natl Cancer Inst. 2009 Apr 1;101(7):519-32
pubmed: 19318631
Nat Rev Cancer. 2007 Oct;7(10):763-77
pubmed: 17882277
J Cell Physiol. 2016 Oct;231(10):2128-41
pubmed: 26844415
Am J Pathol. 2009 Dec;175(6):2618-24
pubmed: 19893031
Am J Pathol. 2014 Mar;184(3):574-83
pubmed: 24388934
EBioMedicine. 2017 Feb;16:51-62
pubmed: 28159572
EBioMedicine. 2015 Jul 02;2(8):808-24
pubmed: 26425687
Radiat Res. 2015 Nov;184(5):482-93
pubmed: 26484401
Cell Metab. 2013 Oct 1;18(4):465-9
pubmed: 23973332
Bioorg Med Chem Lett. 2015 Oct 15;25(20):4363-9
pubmed: 26364942
J Hepatol. 2016 Feb;64(2):333-341
pubmed: 26476289
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Bioorg Med Chem Lett. 2018 Jul 1;28(12):2159-2164
pubmed: 29779975
Nat Commun. 2017 Mar 14;8:14689
pubmed: 28290443
Cancer. 2016 Nov 15;122(22):3430-3446
pubmed: 27622302
Oncologist. 2010;15 Suppl 4:14-22
pubmed: 21115577
Clin Cancer Res. 2015 Dec 15;21(24):5434-8
pubmed: 26519059
Pharmacol Ther. 2017 Sep;177:23-31
pubmed: 28202364
Prog Lipid Res. 2013 Oct;52(4):585-9
pubmed: 24001676
Cell Metab. 2005 May;1(5):309-22
pubmed: 16054078
Cell Cycle. 2017 Mar 19;16(6):499-507
pubmed: 28118080
Eur J Cancer. 2013 Nov;49(16):3412-9
pubmed: 23809766
FEBS J. 2008 Apr;275(7):1556-1567
pubmed: 18312417
J Hepatol. 2009 Jan;50(1):100-10
pubmed: 19008011
Clin Cancer Res. 2007 Dec 1;13(23):7139-45
pubmed: 18056164
Gut. 2020 Jan;69(1):177-186
pubmed: 30954949
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Nat Struct Mol Biol. 2005 Mar;12(3):225-32
pubmed: 15711565